OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 671,968 shares of the company's stock after purchasing an additional 152,681 shares during the period. Dimensional Fund Advisors LP owned 2.77% of OrthoPediatrics worth $15,576,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KIDS. R Squared Ltd acquired a new position in shares of OrthoPediatrics during the fourth quarter valued at approximately $48,000. KLP Kapitalforvaltning AS acquired a new stake in OrthoPediatrics during the 4th quarter worth $79,000. AlphaCentric Advisors LLC purchased a new stake in shares of OrthoPediatrics during the fourth quarter worth $171,000. Wells Fargo & Company MN lifted its stake in shares of OrthoPediatrics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after buying an additional 2,338 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in OrthoPediatrics during the fourth quarter worth about $268,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KIDS. Piper Sandler decreased their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Truist Financial reduced their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Lake Street Capital began coverage on OrthoPediatrics in a research note on Monday, April 7th. They issued a "buy" rating and a $37.00 target price for the company. Needham & Company LLC reissued a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday, May 8th. Finally, Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, OrthoPediatrics has an average rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Trading Down 1.6%

Shares of NASDAQ:KIDS traded down $0.37 during mid-day trading on Wednesday, reaching $22.84. 29,947 shares of the company were exchanged, compared to its average volume of 233,706. The firm has a market cap of $554.72 million, a price-to-earnings ratio of -18.57 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics Corp. has a 1 year low of $20.25 and a 1 year high of $35.99. The firm's 50-day simple moving average is $22.99 and its 200 day simple moving average is $24.04.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.41 million during the quarter, compared to analyst estimates of $51.68 million. Equities research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Insider Activity at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. This trade represents a 2.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $132,006.60. Following the completion of the transaction, the general counsel now directly owns 110,767 shares of the company's stock, valued at $2,753,667.62. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,732 shares of company stock valued at $589,978 over the last 90 days. 32.70% of the stock is owned by corporate insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.